Endometrial Curettage in Abnormal Uterine Bleeding and Efficacy of Progestins for Control in Cases of Hyperplasia

Basit Öğe Kaydı
dc.contributor.authorHaftaci, Simender Mesci
dc.contributor.authorAnkaralı, Handan
dc.contributor.authorYavuzcan, Ali
dc.contributor.authorÇağlar, Mete
dc.date.accessioned2020-05-01T12:11:52Z
dc.date.available2020-05-01T12:11:52Z
dc.date.issued2014
dc.departmentDÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.descriptionAnkarali, Handan Camdeviren/0000-0002-3613-0523en_US
dc.descriptionWOS: 000338633500066en_US
dc.descriptionPubMed: 24870785en_US
dc.description.abstractBackground: Abnormal uterine bleeding (AUB) is the most important symptom of endometrial hyperplasia and endometrial curettage (EC) is the gold standard diagnostic procedure. We present the results of patients who underwent EC for AUB and the efficacy of progestin administration in those with endometrial hyperplasia. Materials and Methods: A total of 415 female patients who presented to Duzce Public Hospital in 2011-2012 for AUB and who underwent EC were included. We determined the reasons for AUB, and females with hyperplasia were treated with 10 mg/day medroxyprogesterone acetate for 14 days/month or 160 mg/day megestrol acetate continuously for 3 months. We evaluated the efficacy of progestins for periods of three and/or six cycles by repeating EC. A statistical analysis of specific endometrial causes according to age of presentation was conducted using the chi-square test. Results: Among the 415 females (average age, 53.5 years) followed for 6 months, 186 had physiological changes (44.8%), 89 had simple hyperplasia (21.44%), 1 had atypical hyperplasia (0.2%), 6 had (1.44%) complex hyperplasia, 3 had (0.72%) atypical complex hyperplasia, and 5 had adenocarcinoma (1.2%). Regression rates were 72.7-100%, and the optimum results were observed after 6 months of hormonal therapy. Conclusions: The main cause of AUB was physiological change. Progestin therapy resulted in significant regression even in females with atypical hyperplasia.en_US
dc.identifier.doi10.7314/APJCP.2014.15.8.3737en_US
dc.identifier.endpage3740en_US
dc.identifier.issn1513-7368
dc.identifier.issue8en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage3737en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2014.15.8.3737
dc.identifier.urihttps://hdl.handle.net/20.500.12684/6228
dc.identifier.volume15en_US
dc.identifier.wosWOS:000338633500066en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAsian Pacific Organization Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal Of Cancer Preventionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAbnormal uterine bleedingen_US
dc.subjectendometrial curettageen_US
dc.subjectendometrial hyperplasiaen_US
dc.subjectMPAen_US
dc.subjectmegestrol acetateen_US
dc.titleEndometrial Curettage in Abnormal Uterine Bleeding and Efficacy of Progestins for Control in Cases of Hyperplasiaen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
6228.pdf
Boyut:
335.75 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu